NTM 1632
Alternative Names: NTM-1632Latest Information Update: 18 Jun 2021
Price :
$50 *
At a glance
- Originator Ology Bioservices
- Developer National Institute of Allergy and Infectious Diseases
- Class Antitoxins; Monoclonal antibodies
- Mechanism of Action Botulinum toxin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Botulism
Most Recent Events
- 10 Dec 2020 No development reported - Phase-I for Botulism (In volunteers, In adults) in USA (IV) (Xoma pipeline, December 2020)